NCT03712189

Brief Summary

This is an unblinded, randomized control study examining two fluid delivery modalities for non-critical female patients with a planned transabdominal pelvic ultrasound requiring intravenous fluid boluses.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 2, 2018

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

October 11, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 19, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2019

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

February 21, 2021

Completed
Last Updated

January 8, 2024

Status Verified

January 1, 2024

Enrollment Period

8 months

First QC Date

October 11, 2018

Results QC Date

January 25, 2021

Last Update Submit

January 4, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Duration- Ultrasound Ordered to Completed

    The primary outcome variable is the duration (minutes) of time from when the ultrasound was ordered to the completion time of the ultrasound.

    From ED (Emergency Department) arrival to discharge/admission, less than 12 hours

Secondary Outcomes (2)

  • Total IV Fluid (mL)

    From ED arrival to discharge/admission, less than 12 hours

  • Duration- Full Bladder

    From ED arrival to discharge/admission, less than 12 hours

Study Arms (2)

Alaris Pump

NO INTERVENTION

Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.

LifeFlow

EXPERIMENTAL

Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.

Device: LifeFlow

Interventions

LifeFlowDEVICE

The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.

LifeFlow

Eligibility Criteria

Age1 Month - 18 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Female patients older than 1 month and less than 18 years
  • Patients require IV crystalloid bolus fluids before a pelvic ultrasound

You may not qualify if:

  • Known cardiac insufficiency or significant cardiac surgery
  • Hepatic insufficiency
  • Renal insufficiency
  • Any known fluid overload states (ascites, pulmonary edema)
  • On any diuretic or antihypertensive therapy
  • Known pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital Los Angeles

Los Angeles, California, 90026, United States

Location

Related Publications (1)

  • Kline M, Crispino L, Bhatnagar A, Panchal RA, Auerbach M. A Randomized Single-Blinded Simulation-Based Trial of a Novel Method for Fluid Administration to a Septic Infant. Pediatr Emerg Care. 2021 Jun 1;37(6):e313-e318. doi: 10.1097/PEC.0000000000001583.

    PMID: 30106868BACKGROUND

MeSH Terms

Conditions

Dehydration

Condition Hierarchy (Ancestors)

Water-Electrolyte ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr Todd P Chang
Organization
Children's Hospital Los Angeles

Study Officials

  • Todd P Chang, MD

    Children's Hospital Los Angeles

    PRINCIPAL INVESTIGATOR
  • Ara Festekjian, MD

    Children's Hospital Los Angeles

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 11, 2018

First Posted

October 19, 2018

Study Start

October 2, 2018

Primary Completion

May 31, 2019

Study Completion

June 30, 2019

Last Updated

January 8, 2024

Results First Posted

February 21, 2021

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations